Varifarma signs an exclusive distribution and license agreement with Recordati for Ledaga® in Argentina. Basel (Switzerland) and Buenos Aires (Argentina) January 25th, 2021 – Laboratorio Varifarma SA, a company focused on complex therapies and orphan diseases, and devoted to increasing the life expectancy of the patient announce they have signed an exclusive distribution and licensing agreement for Ledaga® in Argentina with Recordati AG, Rare Diseases branch, a pharmaceutical company committed to providing often overlooked orphan therapies to the underserved rare disease communities in the World. Ledaga® (chlormethine hydrochloride) is a novel gel formulation, applied once a day, indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare disease characterized by the abnormal accumulation of malignant T-cells in the skin. MFCTCL is the most common type of cutaneous lymphoma and first presents as patches and plaques on the skin. It is difficult to diagnose, particularly in the early stages as many of its features are non-specific. Chlormethine is an alkylating agent that inhibits quickly proliferating cells and Ledaga® is recognized to have a good efficacy profile with a confirmed treatment response achieved in 76.7% of the efficacy evaluable population in the pivotal trial (Lessin S.R. et al JAMA Dermatol. 2013; 149(1): 25-32). Marcelo Conti, Laboratorio Varifarma Director, commented: “It is with great pride and responsibility that we take the license of an innovative product like Ledaga®, from Recordati, in South America. We are anxious to work with a company that shares our principles and work ethic as it aims for great results with a patient-centered approach” About Ledaga® Ledaga® gel is an alkylating drug indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients. Ledaga® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Ledaga® gel is commercialized in the EU since June 2019. Ledaga® is a product licensed to Recordati Rare Diseases by Helsinn Healthcare SA,
Switzerland.